Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $23.75 USD
Change Today -0.40 / -1.66%
Volume 1.3M
As of 4:30 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Spoorstraat 50

Venlo, 5911 KJ


Phone: 31 77 320 8400

Fax: 31 77 320 8409

Sales and Marketing The company markets its products in approximately 100 countries worldwide. It has established subsidiaries in markets that have the sales potential in the Americas, Europe, Australia and Asia. Customers The company sells workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; and Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases, and in some cases translating that research into drug targets or commercial applications. Strategy The company’s strategy for managing innovation focuses on addressing the most significant unmet medical and scientific needs. Intellectual Property As of December 31, 2013, the company owned 233 issued patents in the United States, 156 issued patents in Germany and 889 issued patents in other major industrialized countries. The company had 996 pending patent applications. Regulations The company is subject to a variety of laws and regulations in the European Union, the United States and other countries. The level and scope of the regulation varies depending on the country or defined economic region, but include, among other things, the research, development, testing, clinical trials, manufacture, storage, recordkeeping, approval, labeling, promotion and commercial sales and distribution, of many of its products. Compliance with Fraud and Abuse Laws: The company has to comply with various U.S. federal and state laws, rules and regulations pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Other Fraud and Abuse Laws: The company must comply with a variety of other laws, such as laws prohibiting false claims for reimbursement under Medicare and Medicaid, all of which can also be triggered by violations of federal anti-kickback laws; the Health Insurance Portability and Accounting Act of 1996, which makes it a federal crime to commit healthcare fraud and make false statements; and the Federal Trade Commission Act and similar laws regulating advertisement and consumer protections. Significant Events In May 2014, QIAGEN N.V. announced a collaboration with Eli Lilly and Company to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. In July 2014, Qiagen NV has entered into a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer (NSCLC). In October 2014, Qiagen NV announced a master collaboration agreement with Astellas Pharma Inc. to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. In November 2014, QIAGEN N.V. announced it has entered into a master collaboration agreement with Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline. Competition The company’s competitors include Sigma-Aldrich Corp. and Roche Diagnostics GmbH (Applied Sciences Division). Its competitors also include Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for pro


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QGEN:US $23.75 USD -0.40

QGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $32.71 USD -0.28
BioMerieux €96.11 EUR +0.33
Cepheid $55.25 USD -1.55
Myriad Genetics Inc $34.54 USD +0.01
PerkinElmer Inc $51.21 USD -0.85
View Industry Companies

Industry Analysis


Industry Average

Valuation QGEN Industry Range
Price/Earnings 50.3x
Price/Sales 4.4x
Price/Book 2.1x
Price/Cash Flow 37.9x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at